A Randomized, Placebo-Controlled, Dose Escalating, Phase II Trial of the Anti-HIV-Activity and Safety of VGX-410 (Mifepristone) in HIV-1 Infected Subjects.

Trial Profile

A Randomized, Placebo-Controlled, Dose Escalating, Phase II Trial of the Anti-HIV-Activity and Safety of VGX-410 (Mifepristone) in HIV-1 Infected Subjects.

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Mar 2010

At a glance

  • Drugs Mifepristone (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Inovio Pharmaceuticals
  • Most Recent Events

    • 02 Feb 2010 Actual end date (Nov 2007) and actual number of patients (19) added as reported by ClinicalTrials.gov.
    • 02 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 18 May 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top